CL2007000836A1 - Uso de compuestos derivados de estrobilurina y/o sus sales fisiologicamente toleradas para preparar un medicamento para el tratamiento y/o prevencion de trastornos del metabolismo del hierro. - Google Patents

Uso de compuestos derivados de estrobilurina y/o sus sales fisiologicamente toleradas para preparar un medicamento para el tratamiento y/o prevencion de trastornos del metabolismo del hierro.

Info

Publication number
CL2007000836A1
CL2007000836A1 CL200700836A CL2007000836A CL2007000836A1 CL 2007000836 A1 CL2007000836 A1 CL 2007000836A1 CL 200700836 A CL200700836 A CL 200700836A CL 2007000836 A CL2007000836 A CL 2007000836A CL 2007000836 A1 CL2007000836 A1 CL 2007000836A1
Authority
CL
Chile
Prior art keywords
strobilurine
prevention
prepare
treatment
medicinal product
Prior art date
Application number
CL200700836A
Other languages
English (en)
Inventor
Ravenzwaay Bennard Van Dr M Dr
Original Assignee
Basf Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=38284013&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CL2007000836(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Basf Ag filed Critical Basf Ag
Publication of CL2007000836A1 publication Critical patent/CL2007000836A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/216—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acids having aromatic rings, e.g. benactizyne, clofibrate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5355—Non-condensed oxazines and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A61P39/02—Antidotes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Emergency Medicine (AREA)
  • Toxicology (AREA)
  • Obesity (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Plural Heterocyclic Compounds (AREA)
CL200700836A 2006-03-29 2007-03-28 Uso de compuestos derivados de estrobilurina y/o sus sales fisiologicamente toleradas para preparar un medicamento para el tratamiento y/o prevencion de trastornos del metabolismo del hierro. CL2007000836A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP06111933 2006-03-29

Publications (1)

Publication Number Publication Date
CL2007000836A1 true CL2007000836A1 (es) 2008-05-23

Family

ID=38284013

Family Applications (1)

Application Number Title Priority Date Filing Date
CL200700836A CL2007000836A1 (es) 2006-03-29 2007-03-28 Uso de compuestos derivados de estrobilurina y/o sus sales fisiologicamente toleradas para preparar un medicamento para el tratamiento y/o prevencion de trastornos del metabolismo del hierro.

Country Status (16)

Country Link
US (1) US20100234366A1 (es)
EP (1) EP2001555A1 (es)
JP (1) JP2009531379A (es)
KR (1) KR20080111021A (es)
CN (1) CN101448550A (es)
AR (1) AR060178A1 (es)
AU (1) AU2007233829A1 (es)
BR (1) BRPI0710209A2 (es)
CA (1) CA2646209C (es)
CL (1) CL2007000836A1 (es)
EA (1) EA200801940A1 (es)
IL (1) IL194159A0 (es)
MX (1) MX2008012317A (es)
TW (1) TW200812592A (es)
WO (1) WO2007113170A1 (es)
ZA (1) ZA200809192B (es)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR101290745B1 (ko) 2010-06-03 2013-07-29 한국해양과학기술원 라말린을 함유하는 염증질환 또는 면역질환의 예방 또는 치료용 약학 조성물
US12226505B2 (en) 2018-10-25 2025-02-18 The Procter & Gamble Company Compositions having enhanced deposition of surfactant-soluble anti-dandruff agents
US11433070B2 (en) 2019-06-28 2022-09-06 The Procter & Gamble Company Synergistic anti-inflammatory compositions
WO2021262228A1 (en) 2020-06-26 2021-12-30 The Procter & Gamble Company Synergistic anti-inflammatory compositions
US11701316B2 (en) 2020-12-18 2023-07-18 The Procter & Gamble Company Synergistic anti-inflammatory compositions

Family Cites Families (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US37873A (en) * 1863-03-10 Improvement in hay-presses
US33989A (en) * 1861-12-24 Improvement it machines for punching boiler-plates
US37839A (en) * 1863-03-03 Improved spoke-machine
DE3623921A1 (de) * 1986-07-16 1988-01-21 Basf Ag Oximether und diese enthaltende fungizide
DE3705389A1 (de) * 1987-02-20 1988-09-01 Basf Ag Substituierte crotonsaeureester und diese enthaltende fungizide
DE3823991A1 (de) * 1988-07-15 1990-02-15 Basf Ag Heterocyclisch substituierte (alpha)-aryl-acrylsaeureester und fungizide, die diese verbindungen enthalten
US5194438A (en) * 1988-07-15 1993-03-16 Basf Aktiengesellschaft α-arylacrylates substituted by a trifluoromethylpyrimidinyloxy radical, fungicidal compositions and methods
DE3905911A1 (de) * 1989-02-25 1990-08-30 Basf Ag Neue ss-methoxyacrylate, ihre herstellung und verwendung
PH11991042549B1 (es) * 1990-06-05 2000-12-04
ATE161007T1 (de) * 1990-06-27 1997-12-15 Basf Ag O-benzyl-oximether und diese verbindungen enthaltende pflanzenschutzmittel
DE4030038A1 (de) * 1990-09-22 1992-03-26 Basf Ag Ortho-substituierte phenylessigsaeureamide
DE4117371A1 (de) * 1991-05-28 1992-12-03 Basf Ag Antimykotische mittel, die phenylessigsaeurederivate enthalten
KR100282840B1 (ko) * 1992-01-29 2001-04-02 스타르크, 카르크 카르바메이트및그를함유한작물보호제
DE4318917A1 (de) * 1993-06-07 1994-12-08 Bayer Ag 2-Oximino-2-phenyl-acetamide
SK282153B6 (sk) * 1994-02-04 2001-11-06 Basf Aktiengesellschaft Deriváty kyseliny fenyloctovej, spôsob a medziprodukty ich výroby, ich použitie a prostriedok proti živočíšnym škodcom alebo škodlivým hubám s ich obsahom
CZ292937B6 (cs) * 1994-02-04 2004-01-14 Basf Aktiengesellschaft Deriváty kyseliny fenyloctové, způsob a meziprodukty pro jejich výrobu a činidlo je obsahující
DE4423612A1 (de) * 1994-07-06 1996-01-11 Basf Ag 2-[(Dihydro)pyrazolyl-3'-oxymethylen]-anilide, Verfahren zu ihrer Herstelung und ihre Verwendung
DE19539324A1 (de) * 1995-10-23 1997-04-24 Basf Ag Phenylessigsäurederivate, Verfahren und Zwischenprodukte zu ihrer Herstellung und sie enthaltende Mittel
US6084120A (en) * 1997-07-09 2000-07-04 Hoffmann-La Roche Inc. β-Alkoxyacrylates against malaria
IT1303688B1 (it) * 1998-11-02 2001-02-23 Medidom Lab Derivati aromatici e relativi complessi di fe(iii) atti all'usocome agenti normalizzanti del livello di ferro nell'organismo.
EP1246618A1 (en) * 1999-12-21 2002-10-09 University Of Florida Research Foundation, Inc. N,n'-bis(2-hydroxybenzyl)ethylenediamine-n,n'-diacetic acid in iron chelating therapy
AU2003212325B2 (en) * 2002-03-11 2007-08-23 Basf Aktiengesellschaft Method for immunizing plants against bacterioses
DE10211428A1 (de) * 2002-03-15 2003-10-23 Bayer Ag Bekämpfung von Parasiten an Tieren durch Halogenpyrimidine
JP2005535665A (ja) * 2002-07-09 2005-11-24 ザ スクリプス リサーチ インスティテュート 虚血および再灌流損傷を防止する方法
US20050032903A1 (en) * 2003-08-08 2005-02-10 Suarez-Cervieri Miguel Octavio Method for controlling fungal sieases in legumes
KR100624238B1 (ko) * 2004-06-22 2006-09-19 한국화학연구원 알파-아릴메톡시아크릴레이트 유도체를 함유하는 대사성골 질환의 예방 및 치료용 약학 조성물

Also Published As

Publication number Publication date
TW200812592A (en) 2008-03-16
EP2001555A1 (de) 2008-12-17
CA2646209C (en) 2011-08-16
AR060178A1 (es) 2008-05-28
EA200801940A1 (ru) 2009-04-28
CN101448550A (zh) 2009-06-03
WO2007113170A1 (de) 2007-10-11
US20100234366A1 (en) 2010-09-16
JP2009531379A (ja) 2009-09-03
KR20080111021A (ko) 2008-12-22
IL194159A0 (en) 2011-08-01
CA2646209A1 (en) 2007-10-11
MX2008012317A (es) 2008-10-10
BRPI0710209A2 (pt) 2011-05-24
AU2007233829A1 (en) 2007-10-11
ZA200809192B (en) 2010-01-27

Similar Documents

Publication Publication Date Title
UY31526A1 (es) 4-(4-ciano-2-tioaril)dihidropirimidinonas y su uso
CL2008000198A1 (es) Compuestos derivados de azacicloalcanos, inhibidores de estearoil-coenzima a delta-9; composicion farmaceutica; y uso para el tratamiento de enfermedades tales como diabetes tipo 2, trastorno de lipidos, obesidad y aterosclerosis.
GT201200250A (es) Ariltriazolonas ligadas a bisarilo y su uso
PA8770101A1 (es) Amidas de 4-aril-1,4-dihidro-1, 6-naftiridina sustituidas y su uso
CO6400193A2 (es) Dicianopiridinas alquilamino-sustituidas y sus profármacos de éster de aminoácido
CL2008000981A1 (es) Compuestos derivados de imidazolidin-carboxamida; composicion farmaceutica; procedimiento de produccion de la composicion farmaceutica; y uso en el tratamiento y/o prevencion de trastornos ateroscleroticos, de metabolismo de acidos grasos y en los qu
CL2007002234A1 (es) Compuestos derivados de heterociclos de nitrogeno; composicion farmaceutica que comprende a dicho compuesto; y uso del compuesto para el tratamiento de enfermedades proliferativas.
ATE538652T1 (de) Synergistische pharmazeutische kombination für die behandlung von krebs
BRPI0917444A2 (pt) composições farmacêuticas de retenção gástrica para o tratamento e prevenção de doenas do snc
CL2008000224A1 (es) Composicion farmaceutica que comprende un compuesto derivado glucopiranosilo; y uso para el tratamiento de uno o mas trastornos neurodegenerativos.
CL2012000319A1 (es) Uso de una composición farmaceutica que comprende treprostinil para la preparación de un medicamento para el tratamiento o la prevención de una afección asociada a la fibrosis quística.
UY32535A (es) Métodos e intermediarios para la preparación de agentes farmacéuticos
BR112013029256A8 (pt) combinação farmacêutica para uso no tratamento de pacientes com diabetes tipo 2
CL2007002920A1 (es) Compuestos derivados de 2-aminocarbonilpiridina; composicion farmaceutica; y uso para el tratamiento de trastornos vasculares oclusivos.
AR062402A1 (es) Uso de compuestos y derivados de 2,5-dihidroxibenceno para el tratamiento del cancer de piel
BR112014005025A2 (pt) composição farmacêutica para uso no tratamento de uma doença neurodegenerativa
PL3829628T3 (pl) Kompozycja farmaceutyczna do zastosowania w leczeniu lub zapobieganiu chorobie związanej z C5
CL2007002479A1 (es) Compuestos derivados de pirazol; composicion farmaceutica que comprende a dicho compuesto; y uso del compuesto para el tratamiento de trastornos tromboembolicos.
CL2008000303A1 (es) Compuestos derivados de 1-oxa-3-azaespiro[4.5]decan-2-ona; composicion farmaceutica que comprende a dicho compuesto; y uso del compuesto en el tratamiento de un trastorno de la alimentacion, obesidad, depresion.
CL2007003643A1 (es) Composicion farmaceutica de azimilidina que comprende 0,5% a aproximadamente 2,5% (w/w) de agua; y uso para el tratamiento de arritmias cardiacas.
BRPI0716985A2 (pt) Composição nutricional, uso da mesma, e, suplemento nutricional para o tratamento de pacientes que sofrem de alergias a alimentos
CL2008000982A1 (es) Compuestos derivados de 5-oxo-isoxazol-carboxamida; proceso de preparacion; composicion farmaceutica; procedimiento de produccion de la composicion farmaceutica; y uso en el tratamiento y/o prevencion de trastornos ateroscleroticos, de metabolismo de
CL2008000223A1 (es) Composicion farmaceutica que comprende un compuesto derivado glucopiranosiloxi-pirazol; y uso para el tratamiento de uno o mas trastornos neurodegenerativos.
CL2007003847A1 (es) Compuestos derivados de pirimidinas 2,4,5 tri-sustituidas; composicion farmaceutica que comprende a dichos compuestos; y su uso para el tratamiento del cancer.
BRPI0821454A2 (pt) Formulação farmacêutica, excipiente para a preparação de formulação farmacêuticas de liberação lenta, e, processos para a produção de um excipiente de liberação lenta, e de uma forma farmacêutica.